This article's lead is ready for translation. Click for more information.

Amodiaquine/sulfadoxine/pyrimethamine

From WikiProjectMed
Jump to navigation Jump to search
Amodiaquine/sulfadoxine/pyrimethamine
Combination of
Amodiaquine4-Aminoquinolone[1]
SulfadoxineSulphonamide[1]
PyrimethamineDiaminopyrimidine[1]
Names
Trade namesSpaq-co;[2] others
Clinical data
Main usesPrevent malaria[1]
Side effectsVomiting, abdominal pain, diarrhea, headache, allergic reactions, liver problems, Steven–Johnson syndrome[3]

Amodiaquine/sulfadoxine/pyrimethamine are three medications sold together to prevent malaria.[4][1] Specifically it is used to prevent falciparum malaria in children 3 months to 5 years old in sub-Saharan Africa.[3][1][2] It is taken by mouth.[4] It is given over three days once per month for up to 4 months.[3]

Common side effects include vomiting, abdominal pain, diarrhea, headache, and allergic reactions.[3] Liver problems and Steven–Johnson syndrome may occur.[3] It should not be taken with sulfamethoxazole.[3] Pyrimethamine/sulfadoxine use in early pregnancy may harm the baby; though maybe used in later pregnancy.[3] It contains amodiaquine tablets, which blocks haem detoxification; and pyrimethamine/sulfadoxine tablets, which blocks dihydropteroate synthase and plasmodial dihydrofolate reductase.[3][1]

The combination received World Health Organization prequalification in 2014.[5] It is on the World Health Organization's List of Essential Medicines.[6] Fifty courses of treatment costs about 16 USD as of 2023.[1]

Medical uses

Dosage

It comes in two different strengths of pills.[7]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Amod 153mg+ SP 525mg disp tab/3+1/PAC-50". supply.unicef.org. Archived from the original on 26 March 2023. Retrieved 17 September 2023. Archived 26 March 2023 at the Wayback Machine
  2. ↑ 2.0 2.1 "Amodiaquine (as hydrochloride) 76.5 mg Dispersible Tablets + Pyrimethamine/Sulfadoxine 12.5 mg/250 mg Tablets" (PDF). WHO. Archived (PDF) from the original on 19 September 2023. Retrieved 17 September 2023. Archived 19 September 2023 at the Wayback Machine
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). WHO. Archived (PDF) from the original on 19 September 2023. Retrieved 17 September 2023. Archived 19 September 2023 at the Wayback Machine
  4. ↑ 4.0 4.1 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 4 June 2023. Retrieved 16 September 2023. Archived 4 June 2023 at the Wayback Machine
  5. ↑ "First sulfadoxine/pyrimethamine + amodiaquine prequalified". WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 20 October 2014. Archived from the original on 19 September 2023. Retrieved 18 September 2023. Archived 19 September 2023 at the Wayback Machine
  6. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  7. ↑ "Macleods' Pyrimethamine/Sulfadoxine + Amodiaquine (hydrochloride) dispersible tablets prequalified". WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 4 November 2022. Archived from the original on 19 September 2023. Retrieved 18 September 2023. Archived 19 September 2023 at the Wayback Machine

Retrieved from "https://mdwiki.org/w/index.php?title=Amodiaquine/sulfadoxine/pyrimethamine&oldid=1456307"